USPTO serial 87421067
CYTOMX
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- HESIK, APRIL ANNE
- Law office
- DIVISIONAL UNIT
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with CYTOMX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
South San Francisco, CA
South San Francisco, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Stephanie K. Wade
Stephanie K. Wade Sughrue Mion, PLLC2000 Pennsylvania Ave., Suite 900Washington, DC 20006UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biochemicals for scientific, laboratory, and research use, namely, proteolytically-activatable, protease-activatable, or proteolytically activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells and antigens; diagnostic kits for scientific, laboratory, and research use comprising proteolytically-activatable or protease-activatable, proteolytically-activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells, and antigens; immunoglobulin and antigen-binding fragments for drug conjugation and targeted cell binding for laboratory and research use; assays and reagents for use in scientific, laboratory and research purposes; biochemical test kits comprising assays and reagents for scientific, laboratory and research purposes; assay kits comprising assays and reagents for measuring, monitoring, testing and analyzing proteolytic activation and antibody binding for scientific, laboratory and research use | ACTIVE | — |
| 005 | infections, inflammation; infections, inflammation; infections, inflammation; engineered cell therapies for medical purposes, namely, for use in treating cancer, infections, autoimmunity, and inflammation; infections, inflammation; assays and reagents for use in medical, medical diagnostic and therapeutic purposes for proteolytic activation and binding to tumor cells; biochemical test kits comprised of assays and reagents for medical, medical diagnostic and therapeutic purposes for proteolytic activation and binding to tumor cells; assay kits comprised of assays and reagents for measuring, monitoring, testing and analyzing proteolytic activation, antibody binding, therapeutic treatments and patient recovery for medical, medical diagnostic and therapeutic purposes; assay kits comprised of assays and reagents for use in identifying candidate patient populations for specific therapeutic treatments for medical purposes; therapeutic kits comprising proteolytically-activatable or protease-activatable, proteolytically-activated or protease-activated immunoglobulin and antigen-binding fragments for binding to tissue, cells, and antigens | ACTIVE | — |
| 042 | Scientific research and development in the field of therapeutic biochemicals, engineered cell therapies and immunotherapy, oncology and dysregulated proteolytic activity; medical and scientific research and development for agents, preparations, products and technology in the field of dysregulated proteolytic activities; providing medical and scientific research information in the fields of biochemicals, engineered cell therapies, immunotherapy, oncology and dysregulated proteolytic activity; scientific investigations for medical purposes; medical research; providing scientific and medical research information and analysis relating to biochemicals, engineered cell therapies and immunotherapy, proteolytic activation, antibody binding, therapeutic treatments, patient recovery, and the identification of candidate patients for specific therapeutic treatments; testing, research, design and development services in the field of biochemicals for scientific and medical research purposes; research, design and development of assays for measuring, monitoring, testing and analyzing proteolytic activation, antibody binding, therapeutic treatments and patient recovery, and for identifying candidate patient populations for specific therapeutic treatments; providing technical support and consultation services relating to antibody selection and use, namely, providing technical scientific research consultation services; online computer services in the nature of providing a search engine for obtaining data, namely, searching, retrieving, and providing information on antibodies and research topics pertaining to antibodies on a global computer network | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by CytomX Therapeutics, Inc.
- Other trademarks owned by CytomX Therapeutics, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named CYTOMX
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 29, 2021 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 29, 2021 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Aug 12, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 11, 2020 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Aug 10, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Aug 3, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jul 29, 2020 | EXT5 | SOU EXTENSION 5 FILED | — |
| Jul 29, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 7, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 5, 2020 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Feb 5, 2020 | EXT4 | SOU EXTENSION 4 FILED | — |
| Feb 5, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 30, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 30, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 21, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 21, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 16, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 16, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 22, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 19, 2019 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Aug 19, 2019 | EXT3 | SOU EXTENSION 3 FILED | — |
| Aug 19, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 19, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 15, 2019 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Feb 15, 2019 | EXT2 | SOU EXTENSION 2 FILED | — |
| Feb 15, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 21, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 21, 2018 | NOAC | CORRECTED NOA E-MAILED | — |
| Sep 20, 2018 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Sep 20, 2018 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Sep 17, 2018 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Aug 20, 2018 | EXT1 | SOU EXTENSION 1 FILED | — |
| Aug 20, 2018 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Aug 20, 2018 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Aug 20, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 26, 2018 | CHPB | POST PUBLICATION AMENDMENT - ENTERED | — |
| Feb 20, 2018 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Feb 16, 2018 | APET | ASSIGNED TO PETITION STAFF | — |
| Feb 6, 2018 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Dec 26, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 26, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 6, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 14, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 14, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 14, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 14, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 14, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 9, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 8, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 8, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 24, 2017 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jul 24, 2017 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jul 24, 2017 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jul 17, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 28, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 25, 2017 | NWAP | NEW APPLICATION ENTERED | — |